Week in Review: Cardinal Health Uses M&A to Add Drug Distribution Reach in China
Cardinal Health, a US drug distributor, spent $120 million to acquire six China drug distributors during the last year, paying less than $30 million for each one; 3SBio of Shenyang will be taken private by Dr. Jing Lou, its Chairman and CEO, along with a CITIC Private Equity company; Neusoft, a China software company, will buy out Phillips, its medical imaging JV partner; Zheijang Hisun Pharma will not purchase China rights for Celsion’s cancer drug, which failed its Phase III trial; Grandhope Biotech of Guangzhou in-licensed China rights to an autologous stem cell tendon-repair technology from Orthocell of Australia; CVie Therapeutics, a Lee's Pharma (HK: 00950) subsidiary, bought China rights to a Dyax treatment for hereditary angioedema; Janssen Pharma, a division of Johnson & Johnson, officially opened its China R&D Center in Shanghai Fenglin Life Science Park; and Solasia of Japan received SFDA permission to begin China trials of its anti-nausea patch product. More details…. Stock Symbols: (NYSE: CAH) (NSDQ: SSRX) (SHA: 600718) (SHA: 600267) (NSDQ: CLSN) (SHE: 300238) (NSDQ: DYAX) (NYSE: JNJ) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here